APA (7th ed.) Citation

M, H., L, I., Y, Y., W, F., T, Y., K, M., . . . K, F. (2026). Timing-dependent skin toxicity phenotypes during enfortumab vedotin plus pembrolizumab therapy for advanced urothelial carcinoma. International journal of clinical oncology. https://doi.org/10.1007/s10147-026-03148-2

Chicago Style (17th ed.) Citation

M, Hashimoto, et al. "Timing-dependent Skin Toxicity Phenotypes During Enfortumab Vedotin Plus Pembrolizumab Therapy for Advanced Urothelial Carcinoma." International Journal of Clinical Oncology 2026. https://doi.org/10.1007/s10147-026-03148-2.

MLA (9th ed.) Citation

M, Hashimoto, et al. "Timing-dependent Skin Toxicity Phenotypes During Enfortumab Vedotin Plus Pembrolizumab Therapy for Advanced Urothelial Carcinoma." International Journal of Clinical Oncology, 2026, https://doi.org/10.1007/s10147-026-03148-2.